255 related articles for article (PubMed ID: 10580029)
21. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.
Kern JA; Slebos RJ; Top B; Rodenhuis S; Lager D; Robinson RA; Weiner D; Schwartz DA
J Clin Invest; 1994 Feb; 93(2):516-20. PubMed ID: 7906694
[TBL] [Abstract][Full Text] [Related]
22. Correlation between K-ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma.
Cho JY; Kim JH; Lee YH; Chung KY; Kim SK; Gong SJ; You NC; Chung HC; Roh JK; Kim BS
Cancer; 1997 Feb; 79(3):462-7. PubMed ID: 9028355
[TBL] [Abstract][Full Text] [Related]
23. Molecular staging of non-small cell lung cancer according to K-ras genotypes.
Rosell R; Monzó M; Pifarré A; Ariza A; Sánchez JJ; Moreno I; Maurel J; López MP; Abad A; de Anta JM
Clin Cancer Res; 1996 Jun; 2(6):1083-6. PubMed ID: 9816271
[TBL] [Abstract][Full Text] [Related]
24. K-ras genotypes and prognosis in non-small-cell lung cancer.
Rosell R; Monzo M; Molina F; Martinez E; Pifarre A; Moreno I; Mate JL; de Anta JM; Sanchez M; Font A
Ann Oncol; 1995; 6 Suppl 3():S15-20. PubMed ID: 8616107
[TBL] [Abstract][Full Text] [Related]
25. Low mutational rate of K-ras codon 12 in singular bronchoscopy specimens in suspected lung cancer.
Spasova I; Novotna H; Vachtenheim J; Bartosova H; Patek J; Hoserova V; Zatloukal P; Kinkor Z
Neoplasma; 2005; 52(3):255-9. PubMed ID: 15875089
[TBL] [Abstract][Full Text] [Related]
26. Expression of TLR9 in tumor-infiltrating mononuclear cells enhances angiogenesis and is associated with a worse survival in lung cancer.
Belmont L; Rabbe N; Antoine M; Cathelin D; Guignabert C; Kurie J; Cadranel J; Wislez M
Int J Cancer; 2014 Feb; 134(4):765-77. PubMed ID: 23913633
[TBL] [Abstract][Full Text] [Related]
27. Lung cancer and past occupational exposure to asbestos. Role of p53 and K-ras mutations.
Husgafvel-Pursiainen K; Karjalainen A; Kannio A; Anttila S; Partanen T; Ojajärvi A; Vainio H
Am J Respir Cell Mol Biol; 1999 Apr; 20(4):667-74. PubMed ID: 10100998
[TBL] [Abstract][Full Text] [Related]
28. Prognostic implications of routine, immunohistochemical, and molecular staging in resectable pancreatic adenocarcinoma.
Niedergethmann M; Rexin M; Hildenbrand R; Knob S; Sturm JW; Richter A; Post S
Am J Surg Pathol; 2002 Dec; 26(12):1578-87. PubMed ID: 12459624
[TBL] [Abstract][Full Text] [Related]
29. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
30. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung.
Slebos RJ; Kibbelaar RE; Dalesio O; Kooistra A; Stam J; Meijer CJ; Wagenaar SS; Vanderschueren RG; van Zandwijk N; Mooi WJ
N Engl J Med; 1990 Aug; 323(9):561-5. PubMed ID: 2199829
[TBL] [Abstract][Full Text] [Related]
31. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent.
Mitsudomi T; Steinberg SM; Oie HK; Mulshine JL; Phelps R; Viallet J; Pass H; Minna JD; Gazdar AF
Cancer Res; 1991 Sep; 51(18):4999-5002. PubMed ID: 1654209
[TBL] [Abstract][Full Text] [Related]
32. ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis.
Sugio K; Ishida T; Yokoyama H; Inoue T; Sugimachi K; Sasazuki T
Cancer Res; 1992 May; 52(10):2903-6. PubMed ID: 1581907
[TBL] [Abstract][Full Text] [Related]
33. Association between genetic variants in pre-microRNAs and survival of early-stage NSCLC.
Hong MJ; Choi YY; Jang JA; Jung HJ; Lee SY; Lee WK; Yoo SS; Lee J; Cha SI; Kim CH; Lee E; Jeon HS; Son JW; Park JY
J Thorac Oncol; 2013 Jun; 8(6):703-10. PubMed ID: 23470291
[TBL] [Abstract][Full Text] [Related]
34. K-ras gene point mutation: a stable tumor marker in non-small cell lung carcinoma.
Li S; Rosell R; Urban A; Font A; Ariza A; Armengol P; Abad A; Navas JJ; Monzo M
Lung Cancer; 1994 Jul; 11(1-2):19-27. PubMed ID: 8081702
[TBL] [Abstract][Full Text] [Related]
35. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
[TBL] [Abstract][Full Text] [Related]
36. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer.
Mitsudomi T; Oyama T; Kusano T; Osaki T; Nakanishi R; Shirakusa T
J Natl Cancer Inst; 1993 Dec; 85(24):2018-23. PubMed ID: 8246288
[TBL] [Abstract][Full Text] [Related]
37. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
[TBL] [Abstract][Full Text] [Related]
38. Noninvasive image texture analysis differentiates K-ras mutation from pan-wildtype NSCLC and is prognostic.
Weiss GJ; Ganeshan B; Miles KA; Campbell DH; Cheung PY; Frank S; Korn RL
PLoS One; 2014; 9(7):e100244. PubMed ID: 24987838
[TBL] [Abstract][Full Text] [Related]
39. K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer.
Fukuyama Y; Mitsudomi T; Sugio K; Ishida T; Akazawa K; Sugimachi K
Br J Cancer; 1997; 75(8):1125-30. PubMed ID: 9099959
[TBL] [Abstract][Full Text] [Related]
40. K-ras gene mutations in non-small cell lung cancer in Japanese.
Noda N; Matsuzoe D; Konno T; Kawahara K; Yamashita Y; Shirakusa T
Oncol Rep; 2001; 8(4):889-92. PubMed ID: 11410804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
